Pharmacogenetic study of CES1 gene and enalapril efficacy.
Carboxylesterase 1
Drug efficacy
Enalapril
Genetic variations
Pharmacogenomics
Polymorphisms
Journal
Journal of applied genetics
ISSN: 2190-3883
Titre abrégé: J Appl Genet
Pays: England
ID NLM: 9514582
Informations de publication
Date de publication:
23 Jan 2024
23 Jan 2024
Historique:
received:
06
06
2023
accepted:
12
01
2024
revised:
10
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
aheadofprint
Résumé
Enalapril is an orally administered angiotensin-converting enzyme inhibitor which is widely prescribed to treat hypertension, chronic kidney disease, and heart failure. It is an ester prodrug that needs to be activated by carboxylesterase 1 (CES1). CES1 is a hepatic hydrolase that in vivo biotransforms enalapril to its active form enalaprilat in order to produce its desired pharmacological impact. Several single nucleotide polymorphisms in CES1 gene are reported to alter the catalytic activity of CES1 enzyme and influence enalapril metabolism. G143E, L40T, G142E, G147C, Y170D, and R171C can completely block the enalapril metabolism. Some polymorphisms like Q169P, E220G, and D269fs do not completely block the CES1 function; however, they reduce the catalytic activity of CES1 enzyme. The prevalence of these polymorphisms is not the same among all populations which necessitate to consider the genetic panel of respective population before prescribing enalapril. These genetic variations are also responsible for interindividual variability of CES1 enzyme activity which ultimately affects the pharmacokinetics and pharmacodynamics of enalapril. The current review summarizes the CES1 polymorphisms which influence the enalapril metabolism and efficacy. The structure of CES1 catalytic domain and important amino acids impacting the catalytic activity of CES1 enzyme are also discussed. This review also highlights the importance of pharmacogenomics in personalized medicine.
Identifiants
pubmed: 38261266
doi: 10.1007/s13353-024-00831-w
pii: 10.1007/s13353-024-00831-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.
Références
Alencar RC, Cobas RA, Gomes MB (2010) Allergic reaction related to ramipril use: a case report. Diabetol Metab Syndr 2(1):1–4
doi: 10.1186/1758-5996-2-4
Ann SH, Strauss MH, Park G-M, Han S, Yang Y, Kim Y-G, Won K-B, Kim S-J, Lee S-G, Cho Y-R (2020) Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention. Int J Cardiol 306:35–41
pubmed: 31727411
doi: 10.1016/j.ijcard.2019.11.086
Bruxel E, Salatino-Oliveira A, Genro J, Zeni C, Polanczyk G, Chazan R, Rohde L, Hutz M (2013) Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J 13(5):476–480
pubmed: 22688218
doi: 10.1038/tpj.2012.25
Casey Laizure S, Herring V, Hu Z, Witbrodt K, Parker RB (2013) The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33(2):210–222
pubmed: 23386599
doi: 10.1002/phar.1194
Cha Y-J, Jeong H-E, Shin J-G, Kim E-Y, Yu K-S, Cho J-Y, Yoon SH, Lim KS (2014) Genetic polymorphisms of the carboxylesterase 1 (CES1) gene in a Korean population. Transl Clin Pharmacol 22(1):30–34
doi: 10.12793/tcp.2014.22.1.30
Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC (2021) Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension 78(3):591–603
pubmed: 34304580
doi: 10.1161/HYPERTENSIONAHA.120.16667
Durgin BG, Straub AC (2018) Redox control of vascular smooth muscle cell function and plasticity. Lab Invest 98(10):1254–1262
pubmed: 29463879
pmcid: 6102093
doi: 10.1038/s41374-018-0032-9
El Mangoush M, Singh N, Kumar S, Basha A, Gupta B, Bolya Y, Gamati A (1990) Efficacy of enalapril in essential hypertension and its comparison with atenolol. Postgrad Med J 66(776):446–449
pubmed: 2216994
pmcid: 2429599
doi: 10.1136/pgmj.66.776.446
Faruqi A, Jain A (2021) Enalapril. StatPearls, StatPearls Publishing
Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, McLeod HL, Yokoi T (2008) Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 18(10):911–920
pubmed: 18794728
doi: 10.1097/FPC.0b013e32830b0c5e
Gan C, Wang J, Martínez-Chávez A, Hillebrand M, de Vries N, Beukers J, Wagenaar E, Wang Y, Lebre MC, Rosing H (2023) Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism. Acta Pharm Sin B 13(2):618–631
pubmed: 36873183
doi: 10.1016/j.apsb.2022.10.017
Gordon SG, Kittleson MD (2008) Chapter 17—Drugs used in the management of heart disease and cardiac arrhythmias. In: Maddison JE, Page SW, Church DB (eds) Small Animal Clinical Pharmacology, 2nd edn. W.B. Saunders, Edinburgh, UK, pp 380–457
Her L, Zhu H-J (2020) Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos 48(3):230–244
pubmed: 31871135
pmcid: 7031766
doi: 10.1124/dmd.119.089680
Her LH, Wang X, Shi J, Choi HJ, Jung SM, Smith LS, Wu AH, Bleske BE, Zhu HJ (2021) Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol 87(12):4691–4700
pubmed: 33963573
doi: 10.1111/bcp.14888
Herman LL, Bashir K (2019) Angiotensin converting enzyme inhibitors (ACEI). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL
Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Koyano N, Fujii A, Nagahara Y, Satoh T, Chiba K (2007) Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab Rev 39(1):1–15
pubmed: 17364878
doi: 10.1080/03602530600952164
Ikonnikova A, Rodina T, Dmitriev A, Melnikov E, Kazakov R, Nasedkina T (2022) The influence of the CES1 genotype on the pharmacokinetics of enalapril in patients with arterial hypertension. J Pers Med 12(4):580
pubmed: 35455696
pmcid: 9028383
doi: 10.3390/jpm12040580
Jennings D, Kalus J, Coleman C, Manierski C, Yee J (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy-a meta-analysis. Clin Diabetol 8(6):219–228
Ji Q, Zhang C, Xu Q, Wang Z, Li X, Lv Q (2021) The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol 87(5):2247–2255
pubmed: 33179295
doi: 10.1111/bcp.14646
Labriet A, Lévesque É, Mattia ED, Cecchin E, Jonker D, Couture F, Simonyan D, Buonadonna A, D’Andrea M, Villeneuve L (2019) Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics 20(17):1179–1187
pubmed: 31698983
doi: 10.2217/pgs-2019-0091
Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ (2020) Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis 222(8):1256–1264
pubmed: 32702098
doi: 10.1093/infdis/jiaa447
Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US (2013) The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23(1):1
pubmed: 23111421
pmcid: 3682407
doi: 10.1097/FPC.0b013e32835aa8a2
Li G, Li X, Mahmud I, Ysaguirre J, Fekry B, Wang S, Wei B, Eckel-Mahan KL, Lorenzi PL, Lehner R (2023) Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy. JCI insight 8(2):e163624
Merali Z, Ross S, Paré G (2014) The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metab Drug Interact 29(3):143–151
doi: 10.1515/dmdi-2014-0009
Moore GJ, Pires JM, Kelaidonis K, Gadanec LK, Zulli A, Apostolopoulos V, Matsoukas JM (2021) Receptor interactions of angiotensin II and angiotensin receptor blockers—relevance to COVID-19. Biomolecules 11(7):979
pubmed: 34356603
pmcid: 8301908
doi: 10.3390/biom11070979
Nagy A, Májer R, Boczán J, Sipka S Jr, Szabó A, Enyedi EE, Tatai O, Fagyas M, Papp Z, Csiba L (2023) Enalapril is superior to lisinopril in improving endothelial function without a difference in blood–pressure–lowering effects in newly diagnosed hypertensives. Biomedicines 11(12):3323
pubmed: 38137544
pmcid: 10742010
doi: 10.3390/biomedicines11123323
Nam K, Kim J, Lee S (2022) Genome-wide study on 72,298 individuals in Korean biobank data for 76 traits. Cell Genomics 2(10):100189
pubmed: 36777999
pmcid: 9903843
doi: 10.1016/j.xgen.2022.100189
Nelveg-Kristensen KE, Madsen MB, Torp-Pedersen C, Køber L, Egfjord M, Hansen T, Pedersen O, Rasmussen HB, Hansen PR (2016) Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics 26(4):169–177
pubmed: 26761119
doi: 10.1097/FPC.0000000000000203
Nzabonimpa GS, Rasmussen HB, Brunak S, Taboureau O, I. Consortium (2016)Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches. Drug Metab Pers Ther 31(2):97–106
Organization WH (2021) Hypertension. Retrieved October 28, 2022, from https://www.who.int/news-room/fact-sheets/detail/hypertension
Organization WH (2022) Noncommunicable diseases. Retrieved October 28, 2022, from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
Park S, Kim Y-G, Ann SH, Park HW, Suh J, Roh J-H, Cho Y-R, Han S, Park G-M (2021) Angiotensin-converting enzyme inhibitor–based versus angiotensin receptor blocker–based optimal medical therapy after percutaneous coronary intervention: a nationwide cohort study. J Cardiovasc Pharmacol 77(1):61–68
pubmed: 33165139
doi: 10.1097/FJC.0000000000000930
Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N (2020) ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart J 72(5):345–350
pubmed: 33189192
pmcid: 7670268
doi: 10.1016/j.ihj.2020.08.007
Sambuceti G, Marzilli M, Marraccini P, Schneider-Eicke J, Gliozheni E, Parodi O, L’Abbate A (1997) Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation 95(12):2652–2659
pubmed: 9193434
doi: 10.1161/01.CIR.95.12.2652
Samir A, Aboel-Naga S, Shehata A, Abdelhamid M (2023) Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”. Egypt Heart J 75(1):68
pubmed: 37552407
pmcid: 10409965
doi: 10.1186/s43044-023-00398-7
Sanford JC, Wang X, Shi J, Barrie ES, Wang D, Zhu H-J, Sadee W (2016) Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. Pharmacogenet Genomics 26(5):197
pubmed: 26871237
pmcid: 4821783
doi: 10.1097/FPC.0000000000000206
Sanghani SP, Sanghani PC, Schiel MA, Bosron WF (2009) Human carboxylesterases: an update on CES1, CES2 and CES3. Protein Pept Lett 16(10):1207–1214
pubmed: 19508181
doi: 10.2174/092986609789071324
Sear JW (2019) Antihypertensive drugs and vasodilators. In: Hemmings HC, Egan TD (eds) Pharmacology and Physiology for Anesthesia Foundations and Clinical Application, 2nd edn. Saunders, Philadelphia, PA, USA, pp 535–555
Shi J, Wang X, Eyler RF, Liang Y, Liu L, Mueller BA, Zhu HJ (2016a) Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms. Basic Clin Pharmacol Toxicol 119(6):555–561
pubmed: 27228223
pmcid: 5118077
doi: 10.1111/bcpt.12625
Shi J, Wang X, Nguyen J-H, Bleske BE, Liang Y, Liu L, Zhu H-J (2016b) Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol 119:76–84
pubmed: 27614009
pmcid: 5061634
doi: 10.1016/j.bcp.2016.09.003
Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu H-J (2016c) Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos 44(4):554–559
pubmed: 26817948
pmcid: 4810765
doi: 10.1124/dmd.115.068536
Stage C, Jürgens G, Guski LS, Thomsen R, Bjerre D, Ferrero‐Miliani L, Lyauk YK, Rasmussen HB, Dalhoff K, I. Consortium (2017) The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharmacol 83(7):1506–1514
Sun W, Zhang H, Guo J, Zhang X, Zhang L, Li C, Zhang L (2016) Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: a PRISMA-compliant network meta-analysis. Medicine 95(6):e2554
pubmed: 26871774
pmcid: 4753869
doi: 10.1097/MD.0000000000002554
Swedberg K, Kjekshus J, C. T. S. Group (1988) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).Am J Cardiol 62(2):60A–66A
Tarkiainen EK, Tornio A, Holmberg MT, Launiainen T, Neuvonen PJ, Backman JT, Niemi M (2015) Effect of carboxylesterase 1 c. 428G> A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol 80(5):1131–1138
pubmed: 25919042
pmcid: 4631185
doi: 10.1111/bcp.12667
Thomsen R, Rasmussen HB, Linnet K, I. Consortium (2014) In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.Drug Metab Dispos 42(1):126–133
Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, Zhu H-J (2016) CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Pharmacogenomics J 16(3):220–230
pubmed: 26076923
doi: 10.1038/tpj.2015.42
Wang X, Rida N, Shi J, Wu AH, Bleske BE, Zhu H-J (2017) A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metab Dispos 45(11):1149–1155
pubmed: 28838926
pmcid: 5637814
doi: 10.1124/dmd.117.077669
Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L (2018) Human carboxylesterases: a comprehensive review. Acta Pharm Sin B 8(5):699–712
pubmed: 30245959
pmcid: 6146386
doi: 10.1016/j.apsb.2018.05.005
Wang X, Shi J, Zhu HJ (2019) Functional study of carboxylesterase 1 protein isoforms. Proteomics 19(4):1800288
doi: 10.1002/pmic.201800288
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71(19):e127–e248
pubmed: 29146535
doi: 10.1016/j.jacc.2017.11.006
White CM (1998) Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 18(3):588–599
pubmed: 9620109
doi: 10.1002/j.1875-9114.1998.tb03121.x
Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67(3):799–812
pubmed: 15698420
doi: 10.1111/j.1523-1755.2005.00145.x
Xiao F-Y, Luo J-Q, Liu M, Chen B-L, Cao S, Liu Z-Q, Zhou H-H, Zhou G, Zhang W (2017) Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep 7(1):7244
pubmed: 28775293
pmcid: 5543069
doi: 10.1038/s41598-017-07736-1
Yoshimura M, Kimura T, Ishii M, Ishii K, Matsuura T, Geshi E, Hosokawa M, Muramatsu M (2008) Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochem Biophys Res Commun 369(3):939–942
pubmed: 18328811
doi: 10.1016/j.bbrc.2008.02.120
Zhu H-J, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013) Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344(3):665–672
pubmed: 23275066
doi: 10.1124/jpet.112.201640